5 Key Takeaways
-
1
The iDose TREX is a sustained-release travoprost implant presented at the 2026 American Glaucoma Society meeting.
-
2
Early study results showed a 44% reduction in intraocular pressure (IOP) at 11 days and a 37% reduction at 6 weeks.
-
3
The mean baseline IOP was 24.3 mmHg, dropping to 10.8 mmHg after 11 days.
-
4
No adverse events were reported during the study, indicating a favorable safety profile.
-
5
iDose TREX has double the drug capacity compared to the existing iDose TR implant currently on the market.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.